GSK To Develop LymphoStat-B With Human Genome Sciences
This article was originally published in The Pink Sheet Daily
Executive Summary
Human monoclonal antibody is in clinical development for the treatment of rheumatoid arthritis and systematic lupus erythematosus. The two firms will share jointly in Phase III and IV development costs, as well as in sales and profits.